EMA recommends five new medicines, including a first-in-class small interfering RNA treatment
The EMA’s April meeting of the Medicinal Products for Human Use Committee (CHMP) recommended five new medicines and nine existing medicines with extended therapeutic indications for approval. The new medicines include a gene therapy for spinal muscular atrophy (SMA) - Itvisma




























